1. Certain public‐reported immune‐mediated adverse events for PD‐1 inhibitors in melanoma occur at higher rates than in clinical trials. (12th June 2021) Authors: Gupta, N.; Cullison, C.; Mally, A.; Xiang, L.; Hill, S.T.; Beveridge, M.G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 10(2021) Page Start: e667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗